PRIMO 2022 | Choosing immunotherapy as front line therapy for non-actionable NSCLC
Whilst patients with molecular drivers receive tyrosine kinase inhibitors (TKIs), patients without such mutations receive immunotherapy. Paul Bunn, MD, University of Colorado Cancer Center, Aurora, CO, discusses the efficacy of immunotherapy with chemotherapy in patients with non-small cell lung cancer (NSCLC) without driver mutations. Despite multiple trials having demonstrated the efficacy of pembrolizumab, atezolizumab, cemiplimab alone, there are no trials assessing chemotherapy alone against in combination immunotherapy. The CheckMate 227 (NCT02477826) has suggested that nivolumab plus ipilimumab was beneficial in patients with a PD-L1 tumor proportion score (TPS) of less than 1%, but was statistically insignificant. This interview took place at the 7th Annual Practical Recommendations in Immuno and Molecular Oncology Meeting (PRIMO 2022).
Disclosures
Dr Bunn reports is a member of the DMC committees of Merck, and BMS; has received consulting fees from AZ, Lilly, Ascentage, CStone, viecure, and Imidex; and is on the Board of Directors of Verastem.
